NASDAQ
12.05.26 | 21:59
16,170 US-Dollar
+9,78 % +1,440
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | CGEM Forum Reveals Only 6,000 Moroccan Firms Export, a Path to Change chartered | 2 | North Africa Post | ||
| Do | Cullinan Therapeutics GAAP EPS of -$0.75 | 2 | Seeking Alpha | ||
| Do | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| Do | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.03. | Gilead-Deal untermauert Potenzial: Clear Street bestätigt Kaufempfehlung für Cullinan Oncology | 18 | Investing.com Deutsch | ||
| CULLINAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 24.03. | Clear Street reiterates Cullinan Oncology stock rating on Gilead deal validation | 7 | Investing.com | ||
| 10.03. | Cullinan Therapeutics: Q4 Earnings Insights | 3 | Benzinga.com | ||
| 10.03. | Stifel raises Cullinan Oncology stock price target on autoimmune progress | 2 | Investing.com | ||
| 10.03. | Cullinan Therapeutics GAAP EPS of -$0.77 misses by $0.05 | 1 | Seeking Alpha | ||
| 10.03. | Cullinan Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 10.03. | Cullinan Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.03. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.02. | Guggenheim stuft Cullinan Oncology mit "Kaufen" ein und sieht 151 % Kurspotenzial | 10 | Investing.com Deutsch | ||
| 02.02. | Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target | 9 | Investing.com | ||
| 08.01. | Cullinan Therapeutics: Wichtige Studiendaten zu Autoimmun- und Krebstherapien für 2026 geplant | 4 | Investing.com Deutsch | ||
| 08.01. | Cullinan Therapeutics plans data readouts for key autoimmune programs | 2 | Investing.com | ||
| 08.01. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones | 764 | GlobeNewswire (Europe) | Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended... ► Artikel lesen | |
| 08.01. | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.12.25 | Cowen reiterates Buy rating on Cullinan Oncology stock after ASH data | 5 | Investing.com | ||
| 08.12.25 | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting | 15 | GlobeNewswire (USA) |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DBV TECHNOLOGIES | 3,456 | -0,80 % | DBV Technologies S.A.: DBV Technologies Reports First Quarter 2026 Financial Results | Châtillon, France, April 30, 2026
DBV Technologies Reports First Quarter 2026 Financial Results
Reported cash and cash equivalents of $229 million as of March 31, 2026 -providing funding into... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 6,300 | -3,37 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates | Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026... ► Artikel lesen | |
| CABALETTA BIO | 3,625 | -5,10 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option No-preconditioning program enrolling in lupus... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 6,855 | +0,51 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update | Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 343,62 | +3,56 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| QIAGEN | 28,800 | +2,27 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Qiagen nach endgültigen Quartalszahlen auf "Equal Weight" mit einem Kursziel von 38 US-Dollar belassen. Analyst... ► Artikel lesen | |
| ERNEXA THERAPEUTICS | 12,150 | +68,52 % | Ernexa Therapeutics Inc.: Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models | CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease... ► Artikel lesen | |
| MODERNA | 45,405 | +1,11 % | Moderna: Hantavirus-Schlagzeilen treiben Impfstoff-Aktie an | Das Hantavirus ist auf einem kleinen Kreuzfahrtschiff im Atlantik ausgebrochen. Die Weltgesundheitsorganisation (WHO) hat inzwischen fünf von acht Verdachtsfällen als offizielle Fälle bestätigt. Aus... ► Artikel lesen | |
| EVOTEC | 5,080 | -2,31 % | Kursexplosion bei Evotec! Sommer-Rally bei Desert Gold? Rheinmetall-Aktie auf 2.000 EUR? | Kursexplosion bei Evotec. Nach positiven News aus einer Wirkstoffforschungskooperation kletterte die Aktie zwischenzeitlich um über 9 %. Damit setzt sich der Aufwärtstrend der vergangenen Wochen fort.... ► Artikel lesen | |
| BIONTECH | 79,70 | +0,63 % | Ihre wichtigsten Termine: Spannende Updates von: Pfizer, PayPal, American Express, Cummins, SAP & Biontech | © Foto: Jeff Chiu/AP/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:00... ► Artikel lesen | |
| CG ONCOLOGY | 72,05 | +3,94 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates | Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 109,03 | -14,54 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,960 | +1,61 % | H.C. Wainwright cuts Summit Therapeutics stock price target on trial risk | ||
| ADMA BIOLOGICS | 8,400 | +6,60 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,390 | -0,38 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | - Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 - - Positive cardiopulmonary results and long-term... ► Artikel lesen |
Das Unternehmen CULLINAN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 16,170 Euro und damit +9,78 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CULLINAN THERAPEUTICS INC finden Sie auf Wallstreet Online.